MGX
Metagenomi Inc.

789
Mkt Cap
$60.83M
Volume
504,843.00
52W High
$4.06
52W Low
$1.23
PE Ratio
-0.68
MGX Fundamentals
Price
$1.62
Prev Close
$1.60
Open
$1.61
50D MA
$1.95
Beta
1.03
Avg. Volume
434,773.21
EPS (Annual)
-$2.09
P/B
0.34
Rev/Employee
$258,886.14
Loading...
Loading...
News
all
press releases
Short Interest in Metagenomi, Inc. (NASDAQ:MGX) Grows By 27.1%
Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,045,457 shares, an...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat Ratings reports. One research...
MarketBeat·23d ago
News Placeholder
Bank of America resets Amazon stock forecast after key meeting
Amazon stock has lost about 8% in a month, despite ending October with a very strong earnings report. The drop in the stock's value is due to artificial intelligence stocks being hit with a sell-off...
TheStreet.com·29d ago
News Placeholder
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·2mo ago
News Placeholder
Metagenomi (NASDAQ:MGX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Metagenomi (NASDAQ:MGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of...
MarketBeat·2mo ago
News Placeholder
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.read more...
Benzinga·2mo ago
News Placeholder
Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of +4.17% and +242.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +19.68% and +10.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest MGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.